In this population-based study of 290 patients diagnosed with prostate cancer before age 55 years, there were two patients with germline protein-truncating BRCA2 mutations, yielding an overall prevalence of 0.69% (95%CI 0.08–2.49%). The gene discussed is BRCA2; the disease is prostate cancer.